The development of COVID-19 treatment
Y Yuan, B Jiao, L Qu, D Yang, R Liu - Frontiers in immunology, 2023 - frontiersin.org
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
Drug treatments for covid-19: living systematic review and network meta-analysis
Objective To compare the effects of treatments for coronavirus disease 2019 (covid-19).
Design Living systematic review and network meta-analysis. Data sources WHO covid-19 …
Design Living systematic review and network meta-analysis. Data sources WHO covid-19 …
[HTML][HTML] ESCMID COVID-19 living guidelines: drug treatment and clinical management
M Bartoletti, O Azap, A Barac, L Bussini… - Clinical microbiology …, 2022 - Elsevier
Abstract Scope In January 2021, the ESCMID Executive Committee decided to launch a new
initiative to develop ESCMID guidelines on several COVID-19-related issues, including …
initiative to develop ESCMID guidelines on several COVID-19-related issues, including …
Potential therapeutic options for COVID-19: an update on current evidence
Abstract SARS-CoV-2, a novel coronavirus, is the agent responsible for the COVID-19
pandemic and is a major public health concern nowadays. The rapid and global spread of …
pandemic and is a major public health concern nowadays. The rapid and global spread of …
Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled …
Background Although almost a year has passed since the Coronavirus disease 2019
(COVID-19) outbreak and promising reports of vaccines have been presented, we still have …
(COVID-19) outbreak and promising reports of vaccines have been presented, we still have …
Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia
MA Pinzón, S Ortiz, H Holguín, JF Betancur… - PloS one, 2021 - journals.plos.org
Background There is no effective therapy for the severe acute respiratory syndrome by
coronavirus 2 (SARS-CoV2) responsible for the Coronavirus disease 2019 (Covid-19). To …
coronavirus 2 (SARS-CoV2) responsible for the Coronavirus disease 2019 (Covid-19). To …
[HTML][HTML] Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
JD Chalmers, ML Crichton… - European respiratory …, 2021 - Eur Respiratory Soc
Introduction Hospitalised patients with coronavirus disease 2019 (COVID-19) as a result of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have a high …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have a high …
How COVID-19 has fundamentally changed clinical research in global health
JJH Park, R Mogg, GE Smith… - The Lancet Global …, 2021 - thelancet.com
COVID-19 has had negative repercussions on the entire global population. Despite there
being a common goal that should have unified resources and efforts, there have been an …
being a common goal that should have unified resources and efforts, there have been an …
Respiratory sequelae of COVID-19: pulmonary and extrapulmonary origins, and approaches to clinical care and rehabilitation
Although the exact prevalence of post-COVID-19 condition (also known as long COVID) is
unknown, more than a third of patients with COVID-19 develop symptoms that persist for …
unknown, more than a third of patients with COVID-19 develop symptoms that persist for …
An overview on the treatments and prevention against COVID-19
Y Panahi, AM Gorabi, S Talaei, F Beiraghdar… - Virology Journal, 2023 - Springer
Background The coronavirus disease 2019 (COVID-19) caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to plague the world. While …
respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to plague the world. While …